ArticlePain and therapy2025

Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical Trials.

John R Ingram et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.